Andrew E. Hendifar BS, BA, MD, MPH

Andrew Hendifar, MD, is developing new therapies for pancreatic cancer and neuroendocrine tumors. Dr. Hendifar has helped form multidisciplinary teams that specialize in the treatment of pancreatic cancer, carcinoid, and neuroendocrine tumors. Dr. Hendifar is the primary investigator for several groundbreaking therapies, including radioimmunotherapy for neuroendocrine tumors, anti-inflammatory therapy for pancreatic cancer, and novel approaches to cancer cachexia.

His national roles include SWOG GI Committee Member and a member of the NIH Neuroendocrine Tumor Task Force. He also serves on the steering committee for the Precision Promise Consortium and chairs the associated Supportive Care Committee. At Cedars Sinai, he leads the Gastrointestinal Disease Research Group and is the founding Director of the Hematology and Oncology Fellowship Program.